Cagrilintide: The Next Big Thing in Weight Loss?
Novo Nordisk's experimental weight-loss drug, cagrilintide, shows major promise in a new study, helping participants shed an average of 28 pounds in just over a year—almost 12% of their body weight! Unlike existing GLP-1 drugs, this weekly shot offers a new approach for adults battling obesity without diabetes. With Phase three trials on the horizon, could cagrilintide be the next big breakthrough in weight loss? Hosted on Acast. See acast.com/privacy for more information.